Streetbeat News

Regulatory

STIM

Neuronetics, Inc. (NASDAQ:STIM) announced that Aetna has updated its TMS coverage to include adolescents aged 15 and older with major depressive disorder. This follows FDA clearance for NeuroStar TMS as a first-line add-on treatment for adolescents aged 15-21. The policy update is effective immediately.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:38 pm

YYAI

Connexa has regained compliance with Nasdaq's bid price requirement following a reverse stock split and 10 days of trading above $1. The Nasdaq delisting determination has been withdrawn.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:37 pm

NISN

Nisun International has regained compliance with Nasdaq's listing requirements, ensuring its continued presence on the exchange.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:34 pm

IEMG

LI

MCHI

NIO

NVDA

XPEV

Chinese EV stocks NIO, XPeng, and Li Auto are trading higher on Monday due to China's central bank cutting key interest rates and Nvidia developing a new AI chip for the Chinese market. Investors can gain exposure to Nio through ETFs like IEMG and MCHI. XPeng has an average 1-year price target of $10.0.

Portfolio Pulse from Anusuya Lahiri

July 22, 2024 | 12:34 pm

EWJ

ICCM

IceCure Medical presented key findings on its ProSense breast cancer treatment at the Japanese Breast Cancer Society meeting, showing high success rates and low recurrence. Terumo Corporation plans to seek regulatory clearance in Japan by Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:33 pm

ACGL

Arch Insurance North America, a subsidiary of Arch Capital Group Ltd. (NASDAQ:ACGL), has received regulatory approval for its acquisition of the U.S. MidCorp and Entertainment insurance businesses of Allianz. The transaction is expected to close on August 1, 2024, pending customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:31 pm

MDXG

MiMedx has published a study in a top journal highlighting the regulatory capabilities of DHACM and LHACM allografts on fibrosis, expanding the understanding of the fibrotic process.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:12 pm

EBS

Emergent BioSolutions announced that the shelf-life of NARCAN Nasal Spray has been extended from 36 months to 48 months in Canada. This extension aims to improve naloxone access amid the opioid epidemic. The updated product has started shipping.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:07 pm

ARQT

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) will host a virtual Key Opinion Leader event on July 29, 2024, to discuss the FDA approval and commercialization plans for ZORYVE® (roflumilast) cream 0.15%, a treatment for atopic dermatitis.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:06 pm

LILM

Lilium and the Saudi Arabian General Authority of Civil Aviation have signed a Memorandum of Understanding (MoU) to develop and implement regulations for eVTOL operations in Saudi Arabia starting in 2026.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:04 pm